Biotech Values

[DewDiligence]

If Momenta succeeds with generic Copaxone, [Teva’s] lost generic-enoxaparin profits would loom much larger.

True; however, shareholder lawsuits in this case would probably be directed at Teva’s lies that Copaxone could not be replicated rather than against Teva’s lies that Teva was on the verge of FDA approval for Lovenox.

I assume the basis of your assessment is founded on the concept that Teva and its stock price will perform well enough that investors will have a hard time demonstrating harm.

Right—Lovenox isn’t material enough to Teva for any such claims to be provable in court.